Operation Brain Trauma Therapy: 2016 Update

Patrick M. Kochanek, Helen Bramlett, C. Edward Dixon, W. Dalton Dietrich, Stefania Mondello, Kevin K.W. Wang, Ronald L. Hayes, Audrey Lafrenaye, John T. Povlishock, Frank C. Tortella, Samuel M. Poloyac, Philip Empey, Deborah A. Shear

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Operation brain trauma therapy (OBTT) is a multi-center, pre-clinical drug and biomarker screening consortium for traumatic brain injury (TBI). Therapies are screened across three rat models (parasagittal fluid percussion injury, controlled cortical impact [CCI], and penetrating ballistic-like brain injury). Operation brain trauma therapy seeks to define therapies that show efficacy across models that should have the best chance in randomized clinical trials (RCTs) and/or to define model-dependent therapeutic effects, including TBI protein biomarker responses, to guide precision medicine-based clinical trials in targeted pathologies. The results of the first five therapies tested by OBTT (nicotinamide, erythropoietin, cyclosporine [CsA], simvastatin, and levetiracetam) were published in the Journal of Neurotrauma. Operation brain trauma therapy now describes preliminary results on four additional therapies (glibenclamide, kollidon-VA64, AER-271, and amantadine). To date, levetiracetam was beneficial on cognitive outcome, histology, and/or biomarkers in two models. The second most successful drug, glibenclamide, improved motor function and histology in CCI. Other therapies showed model-dependent effects (amantadine and CsA). Critically, glial fibrillary acidic protein levels predicted treatment effects. Operation brain trauma therapy suggests that levetiracetam merits additional pre-clinical and clinical evaluation and that glibenclamide and amantadine merit testing in specific TBI phenotypes. Operation brain trauma therapy has established that rigorous, multi-center consortia could revolutionize TBI therapy and biomarker development.

Original languageEnglish (US)
Pages (from-to)303-312
Number of pages10
JournalMilitary Medicine
Volume183
DOIs
StatePublished - Mar 1 2018

Fingerprint

etiracetam
Amantadine
Glyburide
Therapeutics
Biomarkers
Traumatic Brain Injury
Histology
Percussion
Precision Medicine
Preclinical Drug Evaluations
Simvastatin
Niacinamide
Glial Fibrillary Acidic Protein
Therapeutic Uses
Erythropoietin
Brain Injuries
Cyclosporine
Randomized Controlled Trials
Clinical Trials
Pathology

Keywords

  • Biomarker
  • Consortium
  • Multi-center
  • Rat
  • Rigor
  • Therapy
  • Traumatic brain injury

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Kochanek, P. M., Bramlett, H., Dixon, C. E., Dalton Dietrich, W., Mondello, S., Wang, K. K. W., ... Shear, D. A. (2018). Operation Brain Trauma Therapy: 2016 Update. Military Medicine, 183, 303-312. https://doi.org/10.1093/milmed/usx184

Operation Brain Trauma Therapy : 2016 Update. / Kochanek, Patrick M.; Bramlett, Helen; Dixon, C. Edward; Dalton Dietrich, W.; Mondello, Stefania; Wang, Kevin K.W.; Hayes, Ronald L.; Lafrenaye, Audrey; Povlishock, John T.; Tortella, Frank C.; Poloyac, Samuel M.; Empey, Philip; Shear, Deborah A.

In: Military Medicine, Vol. 183, 01.03.2018, p. 303-312.

Research output: Contribution to journalArticle

Kochanek, PM, Bramlett, H, Dixon, CE, Dalton Dietrich, W, Mondello, S, Wang, KKW, Hayes, RL, Lafrenaye, A, Povlishock, JT, Tortella, FC, Poloyac, SM, Empey, P & Shear, DA 2018, 'Operation Brain Trauma Therapy: 2016 Update', Military Medicine, vol. 183, pp. 303-312. https://doi.org/10.1093/milmed/usx184
Kochanek, Patrick M. ; Bramlett, Helen ; Dixon, C. Edward ; Dalton Dietrich, W. ; Mondello, Stefania ; Wang, Kevin K.W. ; Hayes, Ronald L. ; Lafrenaye, Audrey ; Povlishock, John T. ; Tortella, Frank C. ; Poloyac, Samuel M. ; Empey, Philip ; Shear, Deborah A. / Operation Brain Trauma Therapy : 2016 Update. In: Military Medicine. 2018 ; Vol. 183. pp. 303-312.
@article{9912dca92a4d4c70b7d2447ab92523a1,
title = "Operation Brain Trauma Therapy: 2016 Update",
abstract = "Operation brain trauma therapy (OBTT) is a multi-center, pre-clinical drug and biomarker screening consortium for traumatic brain injury (TBI). Therapies are screened across three rat models (parasagittal fluid percussion injury, controlled cortical impact [CCI], and penetrating ballistic-like brain injury). Operation brain trauma therapy seeks to define therapies that show efficacy across models that should have the best chance in randomized clinical trials (RCTs) and/or to define model-dependent therapeutic effects, including TBI protein biomarker responses, to guide precision medicine-based clinical trials in targeted pathologies. The results of the first five therapies tested by OBTT (nicotinamide, erythropoietin, cyclosporine [CsA], simvastatin, and levetiracetam) were published in the Journal of Neurotrauma. Operation brain trauma therapy now describes preliminary results on four additional therapies (glibenclamide, kollidon-VA64, AER-271, and amantadine). To date, levetiracetam was beneficial on cognitive outcome, histology, and/or biomarkers in two models. The second most successful drug, glibenclamide, improved motor function and histology in CCI. Other therapies showed model-dependent effects (amantadine and CsA). Critically, glial fibrillary acidic protein levels predicted treatment effects. Operation brain trauma therapy suggests that levetiracetam merits additional pre-clinical and clinical evaluation and that glibenclamide and amantadine merit testing in specific TBI phenotypes. Operation brain trauma therapy has established that rigorous, multi-center consortia could revolutionize TBI therapy and biomarker development.",
keywords = "Biomarker, Consortium, Multi-center, Rat, Rigor, Therapy, Traumatic brain injury",
author = "Kochanek, {Patrick M.} and Helen Bramlett and Dixon, {C. Edward} and {Dalton Dietrich}, W. and Stefania Mondello and Wang, {Kevin K.W.} and Hayes, {Ronald L.} and Audrey Lafrenaye and Povlishock, {John T.} and Tortella, {Frank C.} and Poloyac, {Samuel M.} and Philip Empey and Shear, {Deborah A.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1093/milmed/usx184",
language = "English (US)",
volume = "183",
pages = "303--312",
journal = "Military Medicine",
issn = "0026-4075",
publisher = "Association of Military Surgeons of the US",

}

TY - JOUR

T1 - Operation Brain Trauma Therapy

T2 - 2016 Update

AU - Kochanek, Patrick M.

AU - Bramlett, Helen

AU - Dixon, C. Edward

AU - Dalton Dietrich, W.

AU - Mondello, Stefania

AU - Wang, Kevin K.W.

AU - Hayes, Ronald L.

AU - Lafrenaye, Audrey

AU - Povlishock, John T.

AU - Tortella, Frank C.

AU - Poloyac, Samuel M.

AU - Empey, Philip

AU - Shear, Deborah A.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Operation brain trauma therapy (OBTT) is a multi-center, pre-clinical drug and biomarker screening consortium for traumatic brain injury (TBI). Therapies are screened across three rat models (parasagittal fluid percussion injury, controlled cortical impact [CCI], and penetrating ballistic-like brain injury). Operation brain trauma therapy seeks to define therapies that show efficacy across models that should have the best chance in randomized clinical trials (RCTs) and/or to define model-dependent therapeutic effects, including TBI protein biomarker responses, to guide precision medicine-based clinical trials in targeted pathologies. The results of the first five therapies tested by OBTT (nicotinamide, erythropoietin, cyclosporine [CsA], simvastatin, and levetiracetam) were published in the Journal of Neurotrauma. Operation brain trauma therapy now describes preliminary results on four additional therapies (glibenclamide, kollidon-VA64, AER-271, and amantadine). To date, levetiracetam was beneficial on cognitive outcome, histology, and/or biomarkers in two models. The second most successful drug, glibenclamide, improved motor function and histology in CCI. Other therapies showed model-dependent effects (amantadine and CsA). Critically, glial fibrillary acidic protein levels predicted treatment effects. Operation brain trauma therapy suggests that levetiracetam merits additional pre-clinical and clinical evaluation and that glibenclamide and amantadine merit testing in specific TBI phenotypes. Operation brain trauma therapy has established that rigorous, multi-center consortia could revolutionize TBI therapy and biomarker development.

AB - Operation brain trauma therapy (OBTT) is a multi-center, pre-clinical drug and biomarker screening consortium for traumatic brain injury (TBI). Therapies are screened across three rat models (parasagittal fluid percussion injury, controlled cortical impact [CCI], and penetrating ballistic-like brain injury). Operation brain trauma therapy seeks to define therapies that show efficacy across models that should have the best chance in randomized clinical trials (RCTs) and/or to define model-dependent therapeutic effects, including TBI protein biomarker responses, to guide precision medicine-based clinical trials in targeted pathologies. The results of the first five therapies tested by OBTT (nicotinamide, erythropoietin, cyclosporine [CsA], simvastatin, and levetiracetam) were published in the Journal of Neurotrauma. Operation brain trauma therapy now describes preliminary results on four additional therapies (glibenclamide, kollidon-VA64, AER-271, and amantadine). To date, levetiracetam was beneficial on cognitive outcome, histology, and/or biomarkers in two models. The second most successful drug, glibenclamide, improved motor function and histology in CCI. Other therapies showed model-dependent effects (amantadine and CsA). Critically, glial fibrillary acidic protein levels predicted treatment effects. Operation brain trauma therapy suggests that levetiracetam merits additional pre-clinical and clinical evaluation and that glibenclamide and amantadine merit testing in specific TBI phenotypes. Operation brain trauma therapy has established that rigorous, multi-center consortia could revolutionize TBI therapy and biomarker development.

KW - Biomarker

KW - Consortium

KW - Multi-center

KW - Rat

KW - Rigor

KW - Therapy

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85045456349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045456349&partnerID=8YFLogxK

U2 - 10.1093/milmed/usx184

DO - 10.1093/milmed/usx184

M3 - Article

C2 - 29635589

AN - SCOPUS:85045456349

VL - 183

SP - 303

EP - 312

JO - Military Medicine

JF - Military Medicine

SN - 0026-4075

ER -